Sugi Predict

Sugi Predict / Compounds / SCHEMBL1456243

SCHEMBL1456243

SCHEMBL1456243

NC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1C(N)=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 1/20 0.42
▸ CES1 P23141 1/20 0.42
▸ POLB P06746 2/20 0.39
▸ LMNA P02545 3/20 0.35
▸ F2 P00734 1/20 0.35
▸ PARP1 P09874 1/20 0.32
▸ SIRT6 Q8N6T7 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ TSHR P16473 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ OR51E2 Q9H255 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ HTT P42858 1/20 0.30
▸ ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10804236 0.93 CES2 (0.42) CES2CES1POLBLMNAF2
SCHEMBL28938074 0.90 CES2 (0.40) CES2CES1POLBLMNAF2
SCHEMBL812433 0.90 POLB (0.41) CES2CES1POLBLMNAF2
SCHEMBL8918066 0.89 HTT (0.42) CES2CES1POLBLMNAF2
SCHEMBL7528694 0.84 CES2 (0.33) CES2CES1POLBF2
SCHEMBL11749620 0.83 LMNA (0.45) CES2CES1POLBLMNAF2
SCHEMBL16122071 0.83 CES2 (0.52) CES2CES1POLBLMNAF2
SCHEMBL19695344 0.83 HDAC1 (0.34) CES2CES1POLBLMNATSHR
SCHEMBL28939091 0.83 CES2 (0.32) CES2CES1POLB
SCHEMBL28841304 0.81 POLB (0.42) CES2CES1POLBALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519170-B2 Compounds for preparing immunological adjuvant EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-08-27 — — US claimed
US-20120232298-A1 COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT FANG FRANCIS G (US) 2012-09-13 — — US claimed
US-8198474-B2 Compounds for preparing immunological adjuvant EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-06-12 — — US claimed
US-20100197951-A1 COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT EISAI R & D MANAGEMENT CO., LTD. (JP) 2010-08-05 — — US claimed
JP-2009502742-A — — 2009-01-29 — — JP claimed
EP-1910387-A1 COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT Eisai Co., Ltd (JP) 2008-04-16 — — EP claimed
US-20070082875-A1 toll-like receptor-4 agonists; vaccines EISAI CO., LTD. (JP) 2007-04-12 — — US claimed
WO-2007005583-A1 COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT EISAI CO., LTD. (JP) 2007-01-11 — — WO claimed
EP-0024016-B1 TETRACHLOROPHTHALAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR BACTERICIDAL USE BAYER AG (DE) 1982-02-24 — — EP claimed
EP-3138844-B1 COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT EISAI R&D MAN CO LTD (JP) 2018-05-02 — — EP disclosed
EP-3138844-A1 COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT Eisai R&D Management Co., Ltd. (JP) 2017-03-08 — — EP disclosed
EP-1910387-B1 COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT EISAI R&D MAN CO LTD (JP) 2016-11-16 — — EP disclosed
US-8962857-B2 Compounds for preparing immunological adjuvant EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-02-24 — — US disclosed
US-20140323739-A1 COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT Eisai R&D Management Co.. Ltd. (JP) 2014-10-30 — — US disclosed
EP-1313752-A2 METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES RIBOZYME PHARMACEUTICALS, INC. (US) 2003-05-28 — — EP disclosed
US-20020150936-A1 Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives RIBOZYME PHARMACEUTICALS, INC. 2002-10-17 — — US disclosed
US-6452046-B2 HEATING 2,3,5,6-TETRACHLORO-1,4-BENZENEDIAMIDE SDS BIOTECH K.K. (JP) 2002-09-17 — — US disclosed
US-20020120129-A1 Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives RIBOZYME PHARMACEUTICALS, INC. 2002-08-29 — — US disclosed
WO-2002018405-A2 METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES RIBOZYME PHARMACEUTICALS, INCORPORATED (US) 2002-03-07 — — WO disclosed
EP-0043488-A1 Derivatives of tetrachlorophthalamide acid, process for their preparation and their use as bactericides BAYER AG (DE) 1982-01-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197951-A1 COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT TLR4, TLR3, TLR1 CES2 4168/4885CES1 3951/4885POLB 3072/4885
US-20070082875-A1 toll-like receptor-4 agonists; vaccines TLR4, TLR3, TLR1 CES2 4388/4885CES1 4095/4885POLB 3074/4885
US-20020120129-A1 Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives PNP, NSUN2, NT5C3B CES2 2052/4885CES1 3077/4885POLB 473/4885
US-20020150936-A1 Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives PNP, NSUN2, NT5C3B CES2 1885/4885CES1 3260/4885POLB 477/4885
US-20140323739-A1 COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT TLR4, TLR3, TLR1 CES2 4231/4885CES1 4068/4885POLB 2867/4885
US-20120232298-A1 COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT TLR4, TLR3, TLR1 CES2 4231/4885CES1 4068/4885POLB 2867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.